SELLAS Life Sciences Group Inc
RXK3
Company Profile
Business description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Contact
7 Times Square
Suite 2503
New YorkNY10036
USAT: +1 646 200-5278
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.00 | 54.90 | -0.61% |
| CAC 40 | 8,124.88 | 56.26 | 0.70% |
| DAX 40 | 24,229.91 | 43.42 | 0.18% |
| Dow JONES (US) | 48,416.56 | 41.49 | -0.09% |
| FTSE 100 | 9,751.31 | 102.28 | 1.06% |
| HKSE | 25,129.53 | 499.35 | -1.95% |
| NASDAQ | 23,057.41 | 137.76 | -0.59% |
| Nikkei 225 | 49,525.76 | 642.35 | -1.28% |
| NZX 50 Index | 13,417.50 | 9.36 | 0.07% |
| S&P 500 | 6,816.51 | 10.90 | -0.16% |
| S&P/ASX 200 | 8,594.20 | 53.10 | -0.61% |
| SSE Composite Index | 3,820.85 | 47.07 | -1.22% |